US62855J1043 - Common Stock
SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...
Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81.
MYGN stock results show that Myriad Genetics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...
Avantor stock had its Relative Strength (RS) Rating upgraded from 78 to 84 Tuesday amid positive Q2 earnings results.
New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast Cancer
New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast Cancer...
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision...
SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks.
SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...
New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health
New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health...
New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancer
New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancer...
SALT LAKE CITY, June 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators ...
Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY,...
Genomics is the future of medicine, creating big opportunity for some of the top genomics stock picks to buy today.